Further studies indicated that ERBB2 i14e could also endow cancer cells with irresponsiveness to trastuzumab, one of the most important targeted drugs for ERBB2 used in clinical treatment for breast cancer for over 20 years. Here, ERBB2 is linked to breast cancer.